- Target: Novel targets are highly preferred; well‑validated targets with clear differentiation will also be considered.
- Modality preference: small molecule > antibody > ADC > TPD > siRNA
- Route of administration: oral > subcutaneous > IV
- Clinical stage priority: NDA > Phase 3 > Phase 2 > Phase 1 > IND‑enabling
- Indication: Multiple Sclerosis (MS)
- Hard requirement: single‑agent efficacy is mandatory; assets only active in combination will not be considered
- Rights preference: Global rights are top priority; ex‑Greater China rights as secondary option.
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
